Skip to main content

Advertisement

SpringerLink
Log in

Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction

  • SI: Genetic Neuroimaging in Aging and Age-Related Diseases
  • Published:
Brain Imaging and Behavior Aims and scope Submit manuscript

Abstract

Alzheimer’s disease (AD) is an increasingly prevalent, fatal neurodegenerative disease that has proven resistant, thus far, to all attempts to prevent it, forestall it, or slow its progression. The ε4 allele of the Apolipoprotein E gene (APOE4) is a potent genetic risk factor for sporadic and late-onset familial AD. While the link between APOE4 and AD is strong, many expected effects, like increasing the risk of conversion from MCI to AD, have not been widely replicable. One critical, and commonly overlooked, feature of the APOE4 link to AD is that several lines of evidence suggest it is far more pronounced in women than in men. Here we review previous literature on the APOE4 by gender interaction with a particular focus on imaging-related studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • 2012 Alzheimer’s disease facts and figures. (2012). Alzheimers Dement, 8(2), 131–168. doi:10.1016/j.jalz.2012.02.001

  • Adamson, M. M., Hutchinson, J. B., Shelton, A. L., Wagner, A. D., & Taylor, J. L. (2011). Reduced hippocampal activity during encoding in cognitively normal adults carrying the APOE varepsilon4 allele. Neuropsychologia, 49(9), 2448–2455. doi:10.1016/j.neuropsychologia.2011.04.022.

    PubMed Central  PubMed  Google Scholar 

  • Aisen, P. S. (2011). Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiology of Aging, 32(Suppl 1), S64–S66. doi:10.1016/j.neurobiolaging.2011.09.008.

    PubMed Central  PubMed  Google Scholar 

  • Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., & Tsopelas, N. D. (2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of Neurology, 65(11), 1509–1517. doi:10.1001/archneur.65.11.1509.

    PubMed Central  PubMed  Google Scholar 

  • Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., & Fox, N. C. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7(3), 270–279. doi:10.1016/j.jalz.2011.03.008.

    PubMed Central  PubMed  Google Scholar 

  • Altmann, A. A., Tian, L., Henderson, V. W., & Greicius, M. D. (2013). APOE genotype by gender interaction revealed in CSF biomarkers and clinical conversion rates in the ADNI database. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 9(4), 245–246.

    Google Scholar 

  • Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., & Yoon, S. Y. (2010). Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. Journal of Neuroscience, 30(41), 13707–13717. doi:10.1523/JNEUROSCI.4040-10.2010.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Anstey, K., & Christensen, H. (2000). Education, activity, health, blood pressure and apolipoprotein E as predictors of cognitive change in old age: a review. Gerontology, 46(3), 163–177.

    CAS  PubMed  Google Scholar 

  • Bai, F., Watson, D. R., Shi, Y., Wang, Y., Yue, C., & Teng, Y. (2011). Specifically progressive deficits of brain functional marker in amnestic type mild cognitive impairment. PLoS One, 6(9), e24271. doi:10.1371/journal.pone.0024271.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., & DeLong, C. (2009). Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. Journal of Neuroscience, 29(21), 6771–6779. doi:10.1523/JNEUROSCI.0887-09.2009.

    CAS  PubMed  Google Scholar 

  • Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., & Fox, N. C. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. New England Journal of Medicine, 367(9), 795–804. doi:10.1056/NEJMoa1202753.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Beaudreau, S. A., Kaci Fairchild, J., Spira, A. P., Lazzeroni, L. C., & O’Hara, R. (2012). Neuropsychiatric symptoms, apolipoprotein E gene, and risk of progression to cognitive impairment, no dementia and dementia: the Aging, Demographics, and Memory Study (ADAMS). International Journal of Geriatric Psychiatry. doi:10.1002/gps.3868.

    PubMed  Google Scholar 

  • Bertram, L., Lill, C. M., & Tanzi, R. E. (2010). The genetics of Alzheimer disease: back to the future. Neuron, 68(2), 270–281. doi:10.1016/j.neuron.2010.10.013.

    CAS  PubMed  Google Scholar 

  • Bertram, L., & Tanzi, R. E. (2012). The genetics of Alzheimer’s disease. Progress in Molecular Biology and Translational Science, 107, 79–100. doi:10.1016/B978-0-12-385883-2.00008-4.

    CAS  PubMed  Google Scholar 

  • Beydoun, M. A., Boueiz, A., Abougergi, M. S., Kitner-Triolo, M. H., Beydoun, H. A., & Resnick, S. M. (2012). Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline. Neurobiology of Aging, 33(4), 720–731. doi:10.1016/j.neurobiolaging.2010.05.017. e724.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Blacker, D., Haines, J. L., Rodes, L., Terwedow, H., Go, R. C., & Harrell, L. E. (1997). ApoE-4 and age at onset of Alzheimer’s disease: the NIMH genetics initiative. Neurology, 48(1), 139–147.

    CAS  PubMed  Google Scholar 

  • Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., et al. (2000). Patterns of brain activation in people at risk for Alzheimer’s disease. New England Journal of Medicine, 343(7), 450–456.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bour, A., Grootendorst, J., Vogel, E., Kelche, C., Dodart, J. C., & Bales, K. (2008). Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behavioural Brain Research, 193(2), 174–182. doi:10.1016/j.bbr.2008.05.008.

    CAS  PubMed  Google Scholar 

  • Brecht, W. J., Harris, F. M., Chang, S., Tesseur, I., Yu, G. Q., & Xu, Q. (2004). Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. Journal of Neuroscience, 24(10), 2527–2534. doi:10.1523/JNEUROSCI.4315-03.2004.

    CAS  PubMed  Google Scholar 

  • Breitner, J. C., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., & Norton, M. C. (1999). APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology, 53(2), 321–331.

    CAS  PubMed  Google Scholar 

  • Bretsky, P. M., Buckwalter, J. G., Seeman, T. E., Miller, C. A., Poirier, J., & Schellenberg, G. D. (1999). Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Disease and Associated Disorders, 13(4), 216–221.

    CAS  PubMed  Google Scholar 

  • Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., & Ahern, G. L. (2009). Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. New England Journal of Medicine, 361(3), 255–263. doi:10.1056/NEJMoa0809437.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., & Patterson, B. W. (2011). Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Science Translational Medicine, 3(89), 89ra57. doi:10.1126/scitranslmed.3002156.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Coker, L. H., Espeland, M. A., Rapp, S. R., Legault, C., Resnick, S. M., & Hogan, P. (2010). Postmenopausal hormone therapy and cognitive outcomes: the Women’s Health Initiative Memory Study (WHIMS). Journal of Steroid Biochemistry and Molecular Biology, 118(4–5), 304–310. doi:10.1016/j.jsbmb.2009.11.007.

    CAS  PubMed  Google Scholar 

  • Corder, E. H., Ghebremedhin, E., Taylor, M. G., Thal, D. R., Ohm, T. G., & Braak, H. (2004). The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Annals of the New York Academy of Sciences, 1019, 24–28. doi:10.1196/annals.1297.005.

    CAS  PubMed  Google Scholar 

  • Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., & Gaskell, P. C., Jr. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics, 7(2), 180–184.

    CAS  PubMed  Google Scholar 

  • Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Jr., & Rimmler, J. B. (1995). Apolipoprotein E, survival in Alzheimer’s disease patients, and the competing risks of death and Alzheimer’s disease. Neurology, 45(7), 1323–1328.

    CAS  PubMed  Google Scholar 

  • Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., & Small, G. W. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261(5123), 921–923.

    CAS  PubMed  Google Scholar 

  • Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., & McCormick, W. C. (1998). Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer’s disease. Neurology, 51(1), 149–153.

    CAS  PubMed  Google Scholar 

  • Crivello, F., Lemaitre, H., Dufouil, C., Grassiot, B., Delcroix, N., & Tzourio-Mazoyer, N. (2010). Effects of ApoE-epsilon4 allele load and age on the rates of grey matter and hippocampal volumes loss in a longitudinal cohort of 1186 healthy elderly persons. NeuroImage, 53(3), 1064–1069. doi:10.1016/j.neuroimage.2009.12.116.

    CAS  PubMed  Google Scholar 

  • Cummings, J. L. (2010). Integrating ADNI results into Alzheimer’s disease drug development programs. Neurobiology of Aging, 31(8), 1481–1492. doi:10.1016/j.neurobiolaging.2010.03.016.

    PubMed Central  PubMed  Google Scholar 

  • Dal Forno, G., Carson, K. A., Brookmeyer, R., Troncoso, J., Kawas, C. H., & Brandt, J. (2002). APOE genotype and survival in men and women with Alzheimer’s disease. Neurology, 58(7), 1045–1050.

    CAS  PubMed  Google Scholar 

  • Damoiseaux, J. S., Prater, K. E., Miller, B. L., & Greicius, M. D. (2012a). Functional connectivity tracks clinical deterioration in Alzheimer’s disease. Neurobiology of Aging, 33(4), 828 e819–830. doi:10.1016/j.neurobiolaging.2011.06.024.

    Google Scholar 

  • Damoiseaux, J. S., Seeley, W. W., Zhou, J., Shirer, W. R., Coppola, G., & Karydas, A. (2012b). Gender modulates the APOE epsilon4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. Journal of Neuroscience, 32(24), 8254–8262. doi:10.1523/JNEUROSCI.0305-12.2012.

    CAS  PubMed Central  PubMed  Google Scholar 

  • den Heijer, T., Oudkerk, M., Launer, L. J., van Duijn, C. M., Hofman, A., & Breteler, M. M. (2002). Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology, 59(5), 746–748.

    Google Scholar 

  • Dennis, N. A., Browndyke, J. N., Stokes, J., Need, A., Burke, J. R., Welsh-Bohmer, K. A., et al. (2010). Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. Alzheimers Dement, 6(4), 303–311. doi:10.1016/j.jalz.2009.07.003.

    PubMed Central  PubMed  Google Scholar 

  • Devanand, D. P., Pelton, G. H., Zamora, D., Liu, X., Tabert, M. H., & Goodkind, M. (2005). Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Archives of Neurology, 62(6), 975–980. doi:10.1001/archneur.62.6.975.

    CAS  PubMed  Google Scholar 

  • Dickson, M. R., Li, J., Wiener, H. W., Perry, R. T., Blacker, D., Bassett, S. S., et al. (2008). A genomic scan for age at onset of Alzheimer’s disease in 437 families from the NIMH Genetic Initiative. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B(6), 784–792. doi:10.1002/ajmg.b.30689.

    PubMed Central  Google Scholar 

  • Drago, V., Babiloni, C., Bartres-Faz, D., Caroli, A., Bosch, B., & Hensch, T. (2011). Disease tracking markers for Alzheimer’s disease at the prodromal (MCI) stage. Journal of Alzheimer’s Disease, 26(Suppl 3), 159–199. doi:10.3233/JAD-2011-0043.

    PubMed  Google Scholar 

  • Drzezga, A., Grimmer, T., Henriksen, G., Muhlau, M., Perneczky, R., & Miederer, I. (2009). Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology, 72(17), 1487–1494. doi:10.1212/WNL.0b013e3181a2e8d0.

    CAS  PubMed  Google Scholar 

  • Du, A. T., Schuff, N., Chao, L. L., Kornak, J., Jagust, W. J., & Kramer, J. H. (2006). Age effects on atrophy rates of entorhinal cortex and hippocampus. Neurobiology of Aging, 27(5), 733–740. doi:10.1016/j.neurobiolaging.2005.03.021.

    PubMed Central  PubMed  Google Scholar 

  • Dumanis, S. B., Tesoriero, J. A., Babus, L. W., Nguyen, M. T., Trotter, J. H., & Ladu, M. J. (2009). ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. Journal of Neuroscience, 29(48), 15317–15322. doi:10.1523/JNEUROSCI.4026-09.2009.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Farlow, M. R. (2010). Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? Alzheimer’s Research & Therapy, 2(3), 15. doi:10.1186/alzrt39.

    Google Scholar 

  • Farlow, M. R., Lahiri, D. K., Poirier, J., Davignon, J., Schneider, L., & Hui, S. L. (1998). Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. Neurology, 50(3), 669–677.

    CAS  PubMed  Google Scholar 

  • Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., & Mayeux, R. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 278(16), 1349–1356.

    CAS  PubMed  Google Scholar 

  • Filippini, N., Ebmeier, K. P., MacIntosh, B. J., Trachtenberg, A. J., Frisoni, G. B., & Wilcock, G. K. (2011). Differential effects of the APOE genotype on brain function across the lifespan. NeuroImage, 54(1), 602–610. doi:10.1016/j.neuroimage.2010.08.009.

    CAS  PubMed  Google Scholar 

  • Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., & Smith, S. M. (2009). Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proceedings of the National Academy of Sciences of the United States of America, 106(17), 7209–7214.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Fleisher, A., Grundman, M., Jack, C. R., Jr., Petersen, R. C., Taylor, C., & Kim, H. T. (2005). Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Archives of Neurology, 62(6), 953–957. doi:10.1001/archneur.62.6.953.

    PubMed  Google Scholar 

  • Ghebremedhin, E., Schultz, C., Thal, D. R., Rub, U., Ohm, T. G., Braak, E., et al. (2001). Gender and age modify the association between APOE and AD-related neuropathology. Neurology, 56(12), 1696–1701.

    CAS  PubMed  Google Scholar 

  • Goldman, J. S., Hahn, S. E., Catania, J. W., LaRusse-Eckert, S., Butson, M. B., & Rumbaugh, M. (2011). Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genetics in Medicine, 13(6), 597–605. doi:10.1097/GIM.0b013e31821d69b8.

    PubMed Central  PubMed  Google Scholar 

  • Gomez-Tortosa, E., Barquero, M. S., Baron, M., Sainz, M. J., Manzano, S., & Payno, M. (2007). Variability of age at onset in siblings with familial Alzheimer disease. Archives of Neurology, 64(12), 1743–1748. doi:10.1001/archneur.64.12.1743.

    PubMed  Google Scholar 

  • Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004). Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: evidence from functional MRI. Proceedings of the National Academy of Sciences of the United States of America, 101(13), 4637–4642.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Guerreiro, R. J., & Hardy, J. (2011). Alzheimer’s disease genetics: lessons to improve disease modelling. Biochemical Society Transactions, 39(4), 910–916. doi:10.1042/BST0390910.

    CAS  PubMed  Google Scholar 

  • Henderson, V. W. (2009). Aging, estrogens, and episodic memory in women. Cognitive and Behavioral Neurology, 22(4), 205–214. doi:10.1097/WNN.0b013e3181a74ce7.

    PubMed Central  PubMed  Google Scholar 

  • Hirono, N., Hashimoto, M., Yasuda, M., Kazui, H., & Mori, E. (2003). Accelerated memory decline in Alzheimer’s disease with apolipoprotein epsilon4 allele. Journal of Neuropsychiatry and Clinical Neurosciences, 15(3), 354–358.

    CAS  PubMed  Google Scholar 

  • Huang, Y. (2010). Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer’s disease. Trends in Molecular Medicine, 16(6), 287–294. doi:10.1016/j.molmed.2010.04.004.

    CAS  PubMed  Google Scholar 

  • Jack, C. R., Jr. (2012). Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology, 263(2), 344–361. doi:10.1148/radiol.12110433.

    PubMed Central  PubMed  Google Scholar 

  • Jack, C. R., Jr., Bernstein, M. A., Borowski, B. J., Gunter, J. L., Fox, N. C., & Thompson, P. M. (2010). Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative. Alzheimers Dement, 6(3), 212–220. doi:10.1016/j.jalz.2010.03.004.

    PubMed Central  PubMed  Google Scholar 

  • Jak, A. J., Houston, W. S., Nagel, B. J., Corey-Bloom, J., & Bondi, M. W. (2007). Differential cross-sectional and longitudinal impact of APOE genotype on hippocampal volumes in nondemented older adults. Dementia and Geriatric Cognitive Disorders, 23(6), 382–389. doi:10.1159/000101340.

    PubMed Central  PubMed  Google Scholar 

  • Jorm, A. F., Mather, K. A., Butterworth, P., Anstey, K. J., Christensen, H., & Easteal, S. (2007). APOE genotype and cognitive functioning in a large age-stratified population sample. Neuropsychology, 21(1), 1–8. doi:10.1037/0894-4105.21.1.1.

    PubMed  Google Scholar 

  • Kang, J. H., & Grodstein, F. (2012). Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiology of Aging, 33(7), 1129–1137. doi:10.1016/j.neurobiolaging.2010.10.007.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Khachaturian, A. S., Corcoran, C. D., Mayer, L. S., Zandi, P. P., & Breitner, J. C. (2004). Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Archives of General Psychiatry, 61(5), 518–524. doi:10.1001/archpsyc.61.5.518.

    CAS  PubMed  Google Scholar 

  • Kleiman, T., Zdanys, K., Black, B., Rightmer, T., Grey, M., & Garman, K. (2006). Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer’s disease: retrospective and prospective analysis. Dementia and Geriatric Cognitive Disorders, 22(1), 73–82. doi:10.1159/000093316.

    PubMed  Google Scholar 

  • Kukolja, J., Thiel, C. M., Eggermann, T., Zerres, K., & Fink, G. R. (2010). Medial temporal lobe dysfunction during encoding and retrieval of episodic memory in non-demented APOE epsilon4 carriers. Neuroscience, 168(2), 487–497. doi:10.1016/j.neuroscience.2010.03.044.

    CAS  PubMed  Google Scholar 

  • Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., & Aisen, P. S. (2010). Comparing predictors of conversion and decline in mild cognitive impairment. Neurology, 75(3), 230–238. doi:10.1212/WNL.0b013e3181e8e8b8.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lehmann, D. J., Refsum, H., Nurk, E., Warden, D. R., Tell, G. S., & Vollset, S. E. (2006). Apolipoprotein E epsilon4 and impaired episodic memory in community-dwelling elderly people: a marked sex difference. The Hordaland Health Study. Journal of Neurology, Neurosurgery and Psychiatry, 77(8), 902–908. doi:10.1136/jnnp.2005.077818.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lemaitre, H., Crivello, F., Dufouil, C., Grassiot, B., Tzourio, C., Alperovitch, A., et al. (2005). No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. NeuroImage, 24(4), 1205–1213. doi:10.1016/j.neuroimage.2004.10.016.

    PubMed  Google Scholar 

  • Lu, P. H., Thompson, P. M., Leow, A., Lee, G. J., Lee, A., & Yanovsky, I. (2011). Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study. Journal of Alzheimer’s Disease, 23(3), 433–442. doi:10.3233/JAD-2010-101398.

    PubMed Central  PubMed  Google Scholar 

  • MacGowan, S. H., Wilcock, G. K., & Scott, M. (1998). Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer’s disease. International Journal of Geriatric Psychiatry, 13(9), 625–630.

    CAS  PubMed  Google Scholar 

  • Machulda, M. M., Jones, D. T., Vemuri, P., McDade, E., Avula, R., & Przybelski, S. (2011). Effect of APOE epsilon4 status on intrinsic network connectivity in cognitively normal elderly subjects. Archives of Neurology, 68(9), 1131–1136. doi:10.1001/archneurol.2011.108.

    PubMed Central  PubMed  Google Scholar 

  • Mayeux, R., Small, S. A., Tang, M., Tycko, B., & Stern, Y. (2001). Memory performance in healthy elderly without Alzheimer’s disease: effects of time and apolipoprotein-E. Neurobiology of Aging, 22(4), 683–689.

    CAS  PubMed  Google Scholar 

  • McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Jr., & Kawas, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7(3), 263–269. doi:10.1016/j.jalz.2011.03.005.

    PubMed Central  PubMed  Google Scholar 

  • Messner, D. A. (2011). Informed Choice in Direct-to-Consumer Genetic Testing for Alzheimer and Other Diseases: Lessons from Two Cases. New Genetics and Society, 30(1), 59–72. doi:10.1080/14636778.2011.552300.

    PubMed Central  PubMed  Google Scholar 

  • Meyer-Lindenberg, A., & Weinberger, D. R. (2006). Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nature Review Neuroscience, 7(10), 818–827.

    CAS  Google Scholar 

  • Moffat, S. D., Szekely, C. A., Zonderman, A. B., Kabani, N. J., & Resnick, S. M. (2000). Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. Neurology, 55(1), 134–136.

    CAS  PubMed  Google Scholar 

  • Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., et al. (2010). APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology, 67(1), 122–131. doi:10.1002/ana.21843.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Mortensen, E. L., & Hogh, P. (2001). A gender difference in the association between APOE genotype and age-related cognitive decline. Neurology, 57(1), 89–95.

    CAS  PubMed  Google Scholar 

  • Nyholt, D. R., Yu, C.-E., & Visscher, P. M. (2008). On Jim Watson’s APOE status: genetic information is hard to hide. European Journal of Human Genetics, 17(2), 147–149.

    PubMed Central  PubMed  Google Scholar 

  • Payami, H., Montee, K. R., Kaye, J. A., Bird, T. D., Yu, C. E., Wijsman, E. M., et al. (1994). Alzheimer’s disease, apolipoprotein E4, and gender. JAMA, 271(17), 1316–1317.

    CAS  PubMed  Google Scholar 

  • Payami, H., Zareparsi, S., Montee, K. R., Sexton, G. J., Kaye, J. A., & Bird, T. D. (1996). Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. American Journal of Human Genetics, 58(4), 803–811.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Peskind, E. R., Li, G., Shofer, J., Quinn, J. F., Kaye, J. A., & Clark, C. M. (2006). Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Archives of Neurology, 63(7), 936–939. doi:10.1001/archneur.63.7.936.

    PubMed  Google Scholar 

  • Petersen, R. C., Smith, G. E., Ivnik, R. J., Tangalos, E. G., Schaid, D. J., & Thibodeau, S. N. (1995). Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA, 273(16), 1274–1278.

    CAS  PubMed  Google Scholar 

  • Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., & Ferris, S. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine, 352(23), 2379–2388. doi:10.1056/NEJMoa050151.

    CAS  PubMed  Google Scholar 

  • Raber, J., Bongers, G., LeFevour, A., Buttini, M., & Mucke, L. (2002). Androgens protect against apolipoprotein E4-induced cognitive deficits. Journal of Neuroscience, 22(12), 5204–5209.

    CAS  PubMed  Google Scholar 

  • Raber, J., Wong, D., Buttini, M., Orth, M., Bellosta, S., & Pitas, R. E. (1998). Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proceedings of the National Academy of Sciences of the United States of America, 95(18), 10914–10919.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Raber, J., Wong, D., Yu, G. Q., Buttini, M., Mahley, R. W., Pitas, R. E., et al. (2000). Apolipoprotein E and cognitive performance. Nature, 404(6776), 352–354. doi:10.1038/35006165.

    CAS  PubMed  Google Scholar 

  • Raskind, M. A., Peskind, E. R., Wessel, T., & Yuan, W. (2000). Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology, 54(12), 2261–2268.

    CAS  PubMed  Google Scholar 

  • Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001). Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 98(6), 3334–3339.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., & Minoshima, S. (1996). Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. New England Journal of Medicine, 334(12), 752–758.

    CAS  PubMed  Google Scholar 

  • Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., & Osborne, D. (2004). Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proceedings of the National Academy of Sciences of the United States of America, 101(1), 284–289. doi:10.1073/pnas.2635903100.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., & Lee, W. (2009). Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 106(16), 6820–6825. doi:10.1073/pnas.0900345106.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Reiman, E. M., Langbaum, J. B., Fleisher, A. S., Caselli, R. J., Chen, K., & Ayutyanont, N. (2011). Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. Journal of Alzheimer’s Disease, 26(Suppl 3), 321–329. doi:10.3233/JAD-2011-0059.

    PubMed Central  PubMed  Google Scholar 

  • Reiman, E. M., Uecker, A., Caselli, R. J., Lewis, S., Bandy, D., & de Leon, M. J. (1998). Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease. Annals of Neurology, 44(2), 288–291. doi:10.1002/ana.410440226.

    CAS  PubMed  Google Scholar 

  • Reinvang, I., Winjevoll, I. L., Rootwelt, H., & Espeseth, T. (2010). Working memory deficits in healthy APOE epsilon 4 carriers. Neuropsychologia, 48(2), 566–573. doi:10.1016/j.neuropsychologia.2009.10.018.

    PubMed  Google Scholar 

  • Reverte, I., Klein, A. B., Ratner, C., Domingo, J. L., & Colomina, M. T. (2012). Behavioral phenotype and BDNF differences related to apoE isoforms and sex in young transgenic mice. Experimental Neurology, 237(1), 116–125. doi:10.1016/j.expneurol.2012.06.015.

    CAS  PubMed  Google Scholar 

  • Rigaud, A.-S., Traykov, L., Latour, F., Couderc, R., Moulin, F., & Forette, F. (2002). Presence or absence of at least one [small element of]4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer’s disease. Pharmacogenetics and Genomics, 12(5), 415–420.

    CAS  Google Scholar 

  • Rijpma, A., Jansen, D., Arnoldussen, I. A. C., Fang, X. T., Wiesmann, M., & Mutsaers, M. P. C. (2013). Sex Differences in Presynaptic Density and Neurogenesis in Middle-Aged ApoE4 and ApoE Knockout Mice. Journal of Neurodegenerative Diseases, 2013, 9. doi:10.1155/2013/531326.

    Google Scholar 

  • Risner, M. E., Saunders, A. M., Altman, J. F., Ormandy, G. C., Craft, S., & Foley, I. M. (2006). Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics Journal, 6(4), 246–254. doi:10.1038/sj.tpj.6500369.

    CAS  PubMed  Google Scholar 

  • Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Sr., Rieck, J. R., Hebrank, A. C., & Diaz-Arrastia, R. (2012). beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology, 78(6), 387–395. doi:10.1212/WNL.0b013e318245d295.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., & Friedhoff, L. T. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology, 50(1), 136–145.

    CAS  PubMed  Google Scholar 

  • Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., & Dal-Bianco, P. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ, 318(7184), 633–638.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., & Raskind, M. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 73(24), 2061–2070. doi:10.1212/WNL.0b013e3181c67808.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Samuraki, M., Matsunari, I., Chen, W. P., Shima, K., Yanase, D., & Takeda, N. (2012). Glucose metabolism and gray-matter concentration in apolipoprotein E epsilon4 positive normal subjects. Neurobiology of Aging, 33(10), 2321–2323. doi:10.1016/j.neurobiolaging.2011.11.020.

    CAS  PubMed  Google Scholar 

  • Saunders, A. M., Strittmatter, W. J., Schmechel, D., George-Hyslop, P. H., Pericak-Vance, M. A., & Joo, S. H. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology, 43(8), 1467–1472.

    CAS  PubMed  Google Scholar 

  • Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., & Petersen, R. C. (2009). Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Annals of Neurology, 65(4), 403–413. doi:10.1002/ana.21610.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sheline, Y. I., Morris, J. C., Snyder, A. Z., Price, J. L., Yan, Z., & D’Angelo, G. (2010). APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. Journal of Neuroscience, 30(50), 17035–17040. doi:10.1523/JNEUROSCI.3987-10.2010.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sloane, P. D., Zimmerman, S., Suchindran, C., Reed, P., Wang, L., Boustani, M., et al. (2002). The public health impact of Alzheimer’s disease, 2000–2050: potential implication of treatment advances. Annual Review of Public Health, 23, 213–231.

    PubMed  Google Scholar 

  • Slooter, A. J., Houwing-Duistermaat, J. J., van Harskamp, F., Cruts, M., Van Broeckhoven, C., & Breteler, M. M. (1999). Apolipoprotein E genotype and progression of Alzheimer’s disease: the Rotterdam Study. Journal of Neurology, 246(4), 304–308.

    CAS  PubMed  Google Scholar 

  • Small, G. W., Ercoli, L. M., Silverman, D. H., Huang, S. C., Komo, S., & Bookheimer, S. Y. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 97(11), 6037–6042.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Small, G. W., Mazziotta, J. C., Collins, M. T., Baxter, L. R., Phelps, M. E., & Mandelkern, M. A. (1995). Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA, 273(12), 942–947.

    CAS  PubMed  Google Scholar 

  • Sorg, C., Riedl, V., Muhlau, M., Calhoun, V. D., Eichele, T., & Laer, L. (2007). Selective changes of resting-state networks in individuals at risk for Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 104(47), 18760–18765.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., & Fagan, A. M. (2011). Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7(3), 280–292. doi:10.1016/j.jalz.2011.03.003.

    PubMed Central  PubMed  Google Scholar 

  • Stern, Y., Brandt, J., Albert, M., Jacobs, D. M., Liu, X., & Bell, K. (1997). The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer’s disease. Annals of Neurology, 41(5), 615–620. doi:10.1002/ana.410410510.

    CAS  PubMed  Google Scholar 

  • Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., et al. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 90(5), 1977–1981.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sunderland, T., Mirza, N., Putnam, K. T., Linker, G., Bhupali, D., & Durham, R. (2004). Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer’s disease: the effect of APOE epsilon4 allele. Biological Psychiatry, 56(9), 670–676. doi:10.1016/j.biopsych.2004.07.021.

    CAS  PubMed  Google Scholar 

  • Swan, G. E., Lessov-Schlaggar, C. N., Carmelli, D., Schellenberg, G. D., & La Rue, A. (2005). Apolipoprotein E epsilon4 and change in cognitive functioning in community-dwelling older adults. Journal of Geriatric Psychiatry and Neurology, 18(4), 196–201. doi:10.1177/0891988705281864.

    PubMed  Google Scholar 

  • Talbot, C., Lendon, C., Craddock, N., Shears, S., Morris, J. C., & Goate, A. (1994). Protection against Alzheimer’s disease with apoE epsilon 2. Lancet, 343(8910), 1432–1433.

    CAS  PubMed  Google Scholar 

  • Tierney, M. C., Szalai, J. P., Snow, W. G., Fisher, R. H., Tsuda, T., & Chi, H. (1996). A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology, 46(1), 149–154.

    CAS  PubMed  Google Scholar 

  • Tilvis, R. S., Strandberg, T. E., & Juva, K. (1998). Apolipoprotein E phenotypes, dementia and mortality in a prospective population sample. Journal of American Geriatrics Society, 46(6), 712–715.

    CAS  Google Scholar 

  • Tohgi, H., Takahashi, S., Kato, E., Homma, A., Niina, R., & Sasaki, K. (1997). Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E epsilon4 allele. Neuroscience Letters, 236(1), 21–24.

    CAS  PubMed  Google Scholar 

  • Trachtenberg, A. J., Filippini, N., Ebmeier, K. P., Smith, S. M., Karpe, F., & Mackay, C. E. (2012). The effects of APOE on the functional architecture of the resting brain. NeuroImage, 59(1), 565–572. doi:10.1016/j.neuroimage.2011.07.059.

    CAS  PubMed  Google Scholar 

  • Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S., & Petersen, R. C. (2010). Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement, 6(3), 230–238. doi:10.1016/j.jalz.2010.03.008.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Tupler, L. A., Krishnan, K. R., Greenberg, D. L., Marcovina, S. M., Payne, M. E., & MacFall, J. R. (2007). Predicting memory decline in normal elderly: genetics, MRI, and cognitive reserve. Neurobiology of Aging, 28(11), 1644–1656. doi:10.1016/j.neurobiolaging.2006.07.001.

    PubMed  Google Scholar 

  • van Duijn, C. M., de Knijff, P., Wehnert, A., De Voecht, J., Bronzova, J. B., & Havekes, L. M. (1995). The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer’s disease and a reduced survival. Annals of Neurology, 37(5), 605–610. doi:10.1002/ana.410370510.

    PubMed  Google Scholar 

  • Van Gerven, P. W., Van Boxtel, M. P., Ausems, E. E., Bekers, O., & Jolles, J. (2012). Do apolipoprotein E genotype and educational attainment predict the rate of cognitive decline in normal aging? A 12-year follow-up of the Maastricht Aging Study. Neuropsychology, 26(4), 459–472. doi:10.1037/a0028685.

    PubMed  Google Scholar 

  • van Meer, P., Acevedo, S., & Raber, J. (2007). Impairments in spatial memory retention of GFAP-apoE4 female mice. Behavioural Brain Research, 176(2), 372–375. doi:10.1016/j.bbr.2006.10.024.

    PubMed Central  PubMed  Google Scholar 

  • Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Trojanowski, J. Q., & Shaw, L. M. (2010). Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology, 75(2), 143–151. doi:10.1212/WNL.0b013e3181e7ca82.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wang, K., Liang, M., Wang, L., Tian, L., Zhang, X., Li, K., et al. (2007). Altered functional connectivity in early Alzheimer’s disease: a resting-state fMRI study. Human Brain Mapping, 28(10), 967–978. doi:10.1002/hbm.20324.

    PubMed  Google Scholar 

  • Wang, P. N., Hong, C. J., Lin, K. N., Liu, H. C., & Chen, W. T. (2011). APOE epsilon4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer’s disease among ethnic Chinese in Taiwan. Journal of Neurology, Neurosurgery and Psychiatry, 82(2), 165–169. doi:10.1136/jnnp.2010.209122.

    PubMed  Google Scholar 

  • Ward, A., Crean, S., Mercaldi, C. J., Collins, J. M., Boyd, D., Cook, M. N., et al. (2012). Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiology, 38(1), 1–17. doi:10.1159/000334607.

    PubMed  Google Scholar 

  • Westlye, E. T., Lundervold, A., Rootwelt, H., Lundervold, A. J., & Westlye, L. T. (2011). Increased hippocampal default mode synchronization during rest in middle-aged and elderly APOE epsilon4 carriers: relationships with memory performance. Journal of Neuroscience, 31(21), 7775–7783. doi:10.1523/JNEUROSCI.1230-11.2011.

    CAS  PubMed  Google Scholar 

  • Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000). Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ, 321(7274), 1445–1449.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yaffe, K., Haan, M., Byers, A., Tangen, C., & Kuller, L. (2000). Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology, 54(10), 1949–1954.

    CAS  PubMed  Google Scholar 

  • Zhang, H. Y., Wang, S. J., Xing, J., Liu, B., Ma, Z. L., & Yang, M. (2009). Detection of PCC functional connectivity characteristics in resting-state fMRI in mild Alzheimer’s disease. Behavioural Brain Research, 197(1), 103–108.

    PubMed  Google Scholar 

  • Zhong, N., & Weisgraber, K. H. (2009). Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. Journal of Biological Chemistry, 284(10), 6027–6031. doi:10.1074/jbc.R800009200.

    CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Functional Imaging in Neuropsychiatric Disorders (FIND) Lab, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA

    Leo Ungar, Andre Altmann & Michael D. Greicius

Authors
  1. Leo Ungar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andre Altmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael D. Greicius
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leo Ungar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ungar, L., Altmann, A. & Greicius, M.D. Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction. Brain Imaging and Behavior 8, 262–273 (2014). https://doi.org/10.1007/s11682-013-9272-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11682-013-9272-x

Keywords

Search

Navigation